Editorial Team

Antibody-Drug Conjugates in NSCLC: Challenges, Failures, and Breakthroughs

Non-small cell lung cancer (NSCLC) is a complex and deadly disease, but recent advances in antibody-drug conjugates (ADCs) are offering new hope for patients. ADCs combine targeted precision with powerful cancer-killing drugs, making them a promising option for treating NSCLC. However, their path to success has been challenging, with setbacks and breakthroughs shaping the therapeutic

Antibody-Drug Conjugates in NSCLC: Challenges, Failures, and Breakthroughs Read More Ā»

Overcome Stage IIIC Ovarian Cancer After 2 years of Misdiagnosis

Charlotte is 31 years old. Diagnosed with ovarian cancer at 27, discovered after an intestinal obstruction, she went through numerous challenges before embarking on the most significant professional project of her life: a social and solidarity-based start-up aimed at gently supporting cancer fighters. Here is a meeting with an entrepreneur brimming with life.

Overcome Stage IIIC Ovarian Cancer After 2 years of Misdiagnosis Read More Ā»